Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. READ MORE

Conferences

Improving provider response to adverse events through an algorithm. 

READ MORE

New research has propelled the advance of novel treatment methods for diseases such as leukemia, lymphoma, and myeloma.

READ MORE

News

Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair.

READ MORE

In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors are more effective and safer than conventional second-line treatment

READ MORE

Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.

READ MORE

A systemic immune response, rather than a local response of a tumor, determines successful remission following cancer immunotherapy.

READ MORE

Research in Review

Human epidermal growth factor receptor 2-targeted therapy results in different objective response rates across cancer types based on mutation variants.

READ MORE

A recent clinical trial of a CAR T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive NHL independent of disease type, stage, or characteristics.

READ MORE

A targeting agent is more effective in improving progression-free survival and overall survival than conventional therapy in older patients with a treatment-naïve B-cell malignancy.

READ MORE

Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.

READ MORE